The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 13

PMID 35692753

Authors

Argyrios Gyftopoulos

Ioannis A Ziogas

Andrew S Barbas

Dimitrios Moris

Affiliations

Soon will be listed here.

Abstract

Irreversible electroporation (IRE) is a local ablative technique used in conjunction with chemotherapy to treat locally advanced pancreatic cancer (LAPC). The combination of IRE and chemotherapy has showed increased overall survival when compared to chemotherapy alone, pointing towards a possible facilitating effect of IRE on chemotherapeutic drug action and delivery. This review aims to present current chemotherapeutic regimens for LAPC and their co-implementation with IRE, with an emphasis on possible molecular augmentative mechanisms of drug delivery and action. Moreover, the potentiating mechanism of IRE on immunotherapy, M1 oncolytic virus and dendritic cell (DC)-based treatments is briefly explored. Investigating the synergistic effect of IRE on currently established treatment regimens as well as newer ones, may present exciting new possibilities for future studies seeking to improve current LAPC treatment algorithms.

Citing Articles

Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma.

Li Y, Lam S, Gao Y, Shore E, Anderson D, Hode T Ann Surg Oncol. 2024; 32(4):2786-2798.

PMID: 39739260 DOI: 10.1245/s10434-024-16742-3.

Combination therapy of irreversible electroporation and cytokine-induced killer cells for treating mice bearing panc02 pancreatic-cancer xenografts.

Wang B, Wang H, Yue L, Chen Q, Dong J, Jiang T Biochem Biophys Rep. 2023; 35:101547.

PMID: 37745985 PMC: 10514433. DOI: 10.1016/j.bbrep.2023.101547.

Irreversible electroporation for the management of pancreatic cancer: Current data and future directions.

Spiliopoulos S, Reppas L, Filippiadis D, Delvecchio A, Conticchio M, Memeo R World J Gastroenterol. 2023; 29(2):223-231.

PMID: 36687122 PMC: 9846938. DOI: 10.3748/wjg.v29.i2.223.

Commentary: The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer.

Granata V, Palaia R, Izzo F Front Oncol. 2022; 12:955444.

PMID: 36185275 PMC: 9521203. DOI: 10.3389/fonc.2022.955444.

References

Michelakos T, Pergolini I, Fernandez-Del Castillo C, Honselmann K, Cai L, Deshpande V . Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2017; 269(4):733-740. DOI: 10.1097/SLA.0000000000002600. View

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S . Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of.... J Hepatobiliary Pancreat Sci. 2013; 20(6):590-600. DOI: 10.1007/s00534-013-0616-0. View

Moris D, Machairas N, Tsilimigras D, Prodromidou A, Ejaz A, Weiss M . Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2019; 26(6):1657-1668. DOI: 10.1245/s10434-019-07261-7. View

Flak R, Fisker R, Bruun N, Stender M, Thorlacius-Ussing O, Petersen L . Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer-Results from a Prospective Cohort. Cancers (Basel). 2021; 13(12). PMC: 8226515. DOI: 10.3390/cancers13122862. View

Fromer M, Hawthorne J, Philips P, Egger M, Scoggins C, McMasters K . An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era. Ann Surg Oncol. 2021; 28(11):6201-6210. DOI: 10.1245/s10434-021-10174-z. View

Morganti S, Tarantino P, Ferraro E, DAmico P, Duso B, Curigliano G . Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol. 2019; 1168:9-30. DOI: 10.1007/978-3-030-24100-1_2. View

Bhutiani N, Agle S, Li Y, Li S, Martin 2nd R . Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J Surg Oncol. 2016; 114(2):181-6. DOI: 10.1002/jso.24288. View

Varadhachary G, Tamm E, Abbruzzese J, Xiong H, Crane C, Wang H . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035-46. DOI: 10.1245/ASO.2006.08.011. View

10.

Rudno-Rudzinska J, Kielan W, Guzinski M, Plochocki M, Antonczyk A, Kulbacka J . New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP) - A pilot preclinical study. Surg Oncol. 2021; 38:101634. DOI: 10.1016/j.suronc.2021.101634. View

11.

Martin 2nd R . Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes. J Vis Surg. 2017; 1:4. PMC: 5638541. DOI: 10.3978/j.issn.2221-2965.2015.05.02. View

12.

Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Gellert K, Ridwelski K . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14):1473-81. DOI: 10.1001/jama.2013.279201. View

13.

Granata V, Fusco R, Piccirillo M, Palaia R, Petrillo A, Lastoria S . Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int J Surg. 2015; 18:230-6. DOI: 10.1016/j.ijsu.2015.04.055. View

14.

Calvet C, Mir L . The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev. 2016; 35(2):165-77. PMC: 4911376. DOI: 10.1007/s10555-016-9615-3. View

15.

Paiella S, De Pastena M, DOnofrio M, Crino S, Pan T, De Robertis R . Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol. 2018; 3:80. PMC: 6232064. DOI: 10.21037/tgh.2018.10.05. View

16.

Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L . Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2017; 68(1):130-139. DOI: 10.1136/gutjnl-2017-314828. View

17.

Geboers B, Scheffer H, Graybill P, Ruarus A, Nieuwenhuizen S, Puijk R . High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology. 2020; 295(2):254-272. DOI: 10.1148/radiol.2020192190. View

18.

Katz M, Marsh R, Herman J, Shi Q, Collison E, Venook A . Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013; 20(8):2787-95. PMC: 5600517. DOI: 10.1245/s10434-013-2886-9. View

19.

Henriksen A, Dyhl-Polk A, Chen I, Nielsen D . Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019; 78:17-30. DOI: 10.1016/j.ctrv.2019.06.005. View

20.

Charalambous P, Moris D, Karachaliou G, Papalampros A, Dimitrokallis N, Tsilimigras D . The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review. Eur J Surg Oncol. 2020; 46(9):1565-1572. DOI: 10.1016/j.ejso.2020.05.017. View